Personalis Inc

Personalis, Inc. (Nasdaq: PSNL) is an advanced genomics company focused on precision oncology. Its assays combine tumor-and-normal profiling with proprietary algorithms to guide cancer care throughout the patient journey.

Its flagship NeXT Personal test is an ultrasensitive, tumor-informed molecular residual disease (MRD) assay designed to detect residual disease and recurrence at the earliest timepoints. NeXT Personal has Medicare coverage for immuno-oncology monitoring and for breast and lung cancer indications. It now offers an optional Real-Time Variant Tracker that identifies resistance and therapeutically targetable variants over time. The company also offers ultra-comprehensive genomic profiling to support targeted therapy selection.

Revenue comes from several streams:
- Pharma testing services for biopharma customers such as Moderna and Merck, which enhance biomarker strategy for drug development.
- Clinical diagnostic testing.
- Population sequencing for the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP).
- Enterprise sales and other revenue.

In July 2026, Personalis entered into an Agreement and Plan of Merger to be acquired by Tempus AI, Inc. As a result, it has suspended financial guidance and quarterly earnings calls. Updated Nov 4, 2026